No Data
Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $34 price target.
AnaptysBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 34.28% Wedbush → $34 Reiterates Outperform → Outperform 04/16/2024 85.62% Leerink Partners → $4
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
AnaptysBio GAAP EPS of -$1.64 Misses by $0.04
Express News | AnaptysBio Q1 2024 Adj EPS $(1.64) Misses $(1.57) Estimate, Sales $7.180M Beat $3.967M Estimate